Cellectis European patent EP 1 485 475 upheld at European Patent Office
Cellectis S.A. has announced that the European Patent Office has upheld European Patent EP 1 485 475 owned by Cellectis and relating to the invention of engineering methods for meganucleases. This method is based on the genetic fusion of meganuclease modules to obtain hybrid meganucleases. In the course of this opposition, the patent underwent a limitation of claims and Cellectis considers appealing this decision. This patent not only broadens the range of genetic targets for the meganucleases but also improves their production and vectorization.
Cellectis CEO André Choulika said, “This decision makes us even more determined in our constant fight to defend our intellectual property rights. Intellectual property is a key value of biotechnology companies and is the launch pad for their growth. Our position means that we are able to invest 80% of our income in very high added value research and development projects.”
To date, Cellectis holds a portfolio of 42 granted patents and more than 130 applications for additional patents pending.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.